Polen Growth Fund Investor Class POLRX

Morningstar Medalist Rating
  • NAV / 1-Day Return $31.84  /  +1.40 %
  • Fund Size $1.5B
  • Adjusted Expense Ratio 1.240%
  • Net Expense Ratio 1.240%
  • Fee Level: Distribution High
  • Share Class Type No Load
  • Morningstar Category Large Growth
  • Equity Style Box (Funds) Large Growth
  • Minimum Initial Investment $3,000
  • Investment Status Open
  • TTM Yield 0.00%
  • Turnover Ratio 49%

Morningstar’s Analysis POLRX

Will POLRX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

Process downgrade tempers a still-compelling quality growth approach.

Analyst Drew Carter

Drew Carter

Analyst

Summary

Polen Focus Growth remains a solid large-growth choice, but lower conviction leads to a Process downgrade to Above Average from High. Unfavorable style headwinds aside, individual stock missteps and being slow to act on conviction have eroded some of our conviction in an otherwise solid quality growth approach. Even so, the strategy still benefits from a deeply experienced team capable of regaining its footing. Investors should pay close attention to fees here, as they vary considerably based on vehicle and share class: US offerings include a mutual fund, an active exchange-traded fund, and separately managed accounts, plus a mutual fund for UCITS investors.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings POLRX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 62.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Microsoft Corp

9.02 143M
Technology

NVIDIA Corp

7.47 119M
Technology

ServiceNow Inc

7.20 115M
Technology

Broadcom Inc

6.44 102M
Technology

Amazon.com Inc

6.03 96M
Consumer Cyclical

Alphabet Inc Class C

5.93 94M
Communication Services

Visa Inc Class A

5.67 90M
Financial Services

Mastercard Inc Class A

5.61 89M
Financial Services

Oracle Corp

4.89 78M
Technology

Eli Lilly and Co

4.67 74M
Healthcare

Sponsor Center